Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046037 alone or with sasanlimab in advanced malignancies
NCT06974734Phase 1Terminated
- Sponsor
- Pfizer
- Start
- May 2025
- Primary completion
- Mar 2026
- Modality
- Immunomodulatory ADCs, Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of PF-08046037 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma and 1 more (6 arms), sponsored by Pfizer. Primary endpoints: Adverse Events, Laboratory Abnormalities and 2 more. Started May 2025; status: terminated.
02
Drugs
PF-08046037
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)melanomapancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06974734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974734.